Global Blood Therapeutics Analyst Coverage
22 rows Global Blood Therapeutics Inc. The Investor Relations website contains information about Global Blood Therapeutics Incs business for stockholders potential investors and financial analysts.
You are now leaving the Global Blood Therapeutics website You are currently leaving our site.

Global blood therapeutics analyst coverage. SVB Leerink began coverage on shares of Global Blood Therapeutics in a research report on Tuesday April 20th. Analyst Raju Prasad noted that the valuation of Global Blood Therapeutics is wholly leveraged to its lead. In a report issued on March 11 Wolfe Research also initiated coverage with a Buy rating on the stock with a 6700 price target.
They set an outperform rating and a 5400 price target for the company. You are now leaving the Global Blood Therapeutics website You are currently leaving our site. Global Blood Therapeutics is a well known stock with plenty of analyst coverage suggesting some visibility into future growth.
Analysts at SVB Leerink assumed coverage on shares of Global Blood Therapeutics NASDAQGBT in a research report issued to clients and investors on Tuesday Benzinga reports. They do not constitute an endorsement or an approval by Global Blood Therapeutics. External links are being provided as a convenience and for informational purposes only.
You are now leaving the Global Blood Therapeutics website You are currently leaving our site. Finally Wolfe Research started coverage on Global Blood Therapeutics in a report on Wednesday March 17th. External links are being provided as a convenience and for informational purposes only.
The Investor Relations website contains information about Global Blood Therapeutics Incs business for stockholders potential investors and financial analysts. Global Blood Therapeutics GBT is a biopharmaceutical company dedicated to the discovery development and delivery of life-changing treatments that provide hope to underserved patient communities. Find the latest analyst research for Global Blood Therapeutics Inc.
According to analysts consensus price target of 8512 Global Blood Therapeutics has a forecasted upside of 1272 from its current price of 3747. So it makes a lot of sense to check out what analysts think Global. External links are being provided as a convenience and for informational purposes only.
The Investor Relations website contains information about Global Blood Therapeutics Incs business for stockholders potential investors and financial analysts. Please note that any. You are now leaving the Global Blood Therapeutics website You are currently leaving our site.
Six research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the companys stock. The word on The Street in general suggests a Moderate Buy analyst consensus rating for Global Blood Therapeutics with a 7838 average price target implying a 715 upside from current levels. Global Blood Therapeutics NASDAQGBT Coverage Initiated at SVB Leerink.
You are now leaving the Global Blood Therapeutics website You are currently leaving our site. Wolfe Research initiated coverage on shares of Global Blood Therapeutics in a research report on Wednesday March 17th. They do not constitute an endorsement or an approval by Global Blood Therapeutics.
They issued an outperform rating and a 6700 target price for the company. External links are being provided as a convenience and for informational purposes only. External links are being provided as a convenience and for informational purposes only.
They do not constitute an endorsement or an approval by Global Blood Therapeutics. The firm set an outperform rating and a 5400 price target on the stock. William Blair Company initiated research coverage of Global Blood Therapeutics Inc.
They do not constitute an endorsement or an approval by Global Blood Therapeutics. They do not constitute an endorsement or an approval by Global Blood Therapeutics. Founded in 2011 GBT is delivering on its goal to transform the treatment and care of sickle cell disease SCD a lifelong devastating inherited blood disorder.
SVB Leerink initiated coverage on shares of Global Blood Therapeutics NASDAQGBT in a research note issued to investors on Wednesday Analyst Price Targets reports. Amount of Analyst Coverage Global Blood Therapeutics has been the subject of 6 research reports in the past 90 days demonstrating strong analyst interest in this stock. The brokerage set an outperform rating and a 5400 price target on the stock.
Is followed by the analysts listed above. GBT 5395 a clinical-stage biopharmaceutical company dedicated to discovering developing and commercializing therapeutics to treat blood-based disorders with significant unmet medical need.
Post a Comment for "Global Blood Therapeutics Analyst Coverage"